cas 1282516-69-1|| where to buy 9-Bromo-5,6-dihydro-2-iodo-imidazo[1,2-d][1,4]benzoxazepine

製品名:9-Bromo-5,6-dihydro-2-iodo-imidazo[1,2-d][1,4]benzoxazepine

IUPAC Name:12-bromo-4-iodo-9-oxa-3,6-diazatricyclo[8.4.0.0²,⁶]tetradeca-1(14),2,4,10,12-pentaene

包装単位	有効在庫	価格（USD）
CM152652-100mg	in stock	ǑƿǑ
CM152652-250mg	in stock	ƃȯƃ
CM152652-10g	in stock	ƃȐǶƿ
CM152652-25g	in stock	ƿƃƛȐ
CM152652-100g	in stock	ǑƥƛǶȯ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1282516-69-1 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:1282516-69-1; 分子式:C11H8BrIN2O; 融点:-; SMILESコード:IC1=CN2CCOC3=CC(Br)=CC=C3C2=N1; 密度:

: カタログ番号:CM152652; 分子量:391.01; 沸点:; MDL番号:MFCD22690733; 保管方法:2-8°C

: Imidazoles; Imidazole is an important five-membered nitrogen-containing heterocyclic compound. Among the numerous heterocyclic compounds, imidazole and its derivatives are regarded as a unique and multifaceted scaffold material due to their diverse applications in industrial, organic and pharmaceutical chemistry. Imidazoles interact in different ways with many therapeutic targets, enzymes and receptors in biological systems and thus exhibit a wide range of biological activities. In particular, several imidazoles can be used as clinical drugs to treat various types of cancer with high therapeutic efficacy. Furthermore, imidazoles are one of the most critical segments in the field of anti-covid-19 virus drug discovery due to their ability to interact with active targets in living systems.; Imidazole Manufacturer; As a professional imidazole manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

: Inavolisib; Genentech’s Phase III results show that the Inavolisib (GDC-0077) treatment meets the primary end point in hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated Breast Cancer. The combination of Inavolisib with Palbociclib and fulvestrant improves the progression-free survival (PFS) in the first line. Inavolisib is a potent selective inhibitor of PI3K alpha (PI3Kα) that binds to the ATP-binding site of p110α, and promotes the degradation of mutated p110α.